SRDX

SRDX - Surmodics Inc Stock Price, Fair Value and News

$42.98 
Market Closed as of 28 Nov 2025, 04:00 pm ET

SRDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SRDX Price Action

SRDX RSI Chart

SRDX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SRDX Valuation

SRDX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SRDX Fundamentals

SRDX Revenue

SRDX Earnings

SRDX Profitability

SRDX Investor Care

Revenue & Growth

How Surmodics Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025121.6M120.8M--
2024143.0M120.8M126.1M125.4M
2023103.0M130.6M132.6M138.2M
202297.0M97.9M100.0M101.9M
2021106.7M103.7M105.1M105.8M
2020100.6M103.1M94.9M94.5M
201990.2M92.3M100.1M100.5M
201873.9M78.4M81.3M86.6M
201773.4M71.2M73.1M72.4M
201666.5M70.6M71.4M72.6M
201558.6M59.9M61.9M64.2M
201456.1M56.4M57.4M57.8M
201356.1M56.1M56.1M56.2M
201254.4M55.7M56.1M56.1M
201153.6M53.2M52.8M54.1M
2010--54.5M54.1M
SRDX
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
 CEO
 WEBSITEsurmodics.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES447